Granted Patent
B2
US 12,310,997 · App. 18/167,598 · Granted May 27, 2025
Compositions and methods of treating ocular diseases
Inventors:
David V. Schaffer (Danville, CA); Leah C. Byrne (San Francisco, CA); Timothy P. Day (Berkeley, CA); John G. Flannery (Berkeley, CA)
A61K35/761A61K9/0048A61K48/0041A61K48/0075A61P27/02C07K7/06C07K7/08C07K14/075C12N9/22C12N15/1082C12N15/11C12N15/113C12N15/86C12N15/902C12N2310/20C12N2750/14122C12N2750/14142C12N2750/14143C12N2750/14145C12N2750/14171C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
Claims (20)
1. A recombinant adeno-associated virus (rAAV) comprising:
a) a variant AAV capsid protein, wherein the variant AAV capsid protein comprises an insertion of a heterologous peptide between amino acids 570 and 611 of VP1 of AAV2 according to SEQ ID NO:1, wherein the heterologous peptide comprises the sequence of LQRGVRIPSVLEVNGQ (SEQ ID NO: 29) or LALIQDSMRA (SEQ ID NO: 35); and
b) a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous gene product.
2. The rAAV of claim 1 , wherein the variant capsid protein confers increased infectivity of a retinal cell compared to the infectivity of the retinal cell by a control AAV comprising the corresponding parental AAV capsid protein.
3. The rAAV of claim 1 , wherein the heterologous peptide comprises the sequence of LALIQDSMRA (SEQ ID NO: 35).
4. The rAAV of claim 1 , wherein the heterologous peptide comprises the sequence of LQRGVRIPSVLEVNGQ (SEQ ID NO: 29).
5. The rAAV of claim 1 , wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of the VP1 of AAV2 according to SEQ ID NO:1.
6. The rAAV of claim 1 , wherein the insertion site is located between amino acids corresponding to amino acids 585 and 598 of the VP1 of AAV2 according to SEQ ID NO:1.
7. The rAAV of claim 1 , wherein gene product is a polypeptide, an interfering RNA or an aptamer.
8. The rAAV of claim 7 , wherein the polypeptide is a neuroprotective polypeptide or an anti-angiogenic polypeptide.
9. The rAAV of claim 7 , wherein the polypeptide is an RNA-guided endonuclease selected from a type II CRISPR/Cas polypeptide, a type V CRISPR/Cas polypeptide, and a type VI CRISPR/Cas polypeptide.
10. The rAAV of claim 9 , wherein the RNA-guided endonuclease is an enzymatically inactive type II CRISPR/Cas polypeptide.
11. The rAAV of claim 1 , wherein the gene product is an RNA-guided endonuclease and a guide RNA.
12. A pharmaceutical composition comprising:
a) the rAAV according to claim 1 ; and
b) a pharmaceutically acceptable excipient.
13. The pharmaceutical composition of claim 12 , comprising from 10 6 to 10 15 rAAV.
14. An isolated nucleic acid comprising a nucleotide sequence that encodes a variant adeno-associated virus (AAV) capsid protein comprising an insertion of a heterologous peptide between amino acids 570 and 611 of VP1 of AAV2 according to SEQ ID NO:1, wherein the heterologous peptide comprises the sequence of LQRGVRIPSVLEVNGQ (SEQ ID NO: 29) or LALIQDSMRA (SEQ ID NO: 35).
15. An isolated host cell comprising the nucleic acid of claim 14 .
16. A method of delivering a gene product to a retinal cell in an individual, the method comprising administering to the individual the recombinant adeno-associated virus (rAAV) of claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 5, 2023
From: SCHAFFER, DAVID V.; BYRNE, LEAH C.; DAY, TIMOTHY P.; FLANNERY, JOHN G.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 063555/0124 →
Continuity (4)
Continuation
16486681
Provisional Application
62535042
· Jul 20, 2017
Provisional Application
62527871
· Jun 30, 2017
References Cited (336)
US 5773700A
· Grinsven et al.
· 1998
[cited by applicant]
US 6096548A
· Stemmer
· 2000
[cited by applicant]
US 6482634B1
· Wilson et al.
· 2002
[cited by applicant]
US 6491907B1
· Rabinowitz et al.
· 2002
[cited by applicant]
US 6596539B1
· Stemmer et al.
· 2003
[cited by applicant]
US 6703237B2
· Samulski et al.
· 2004
[cited by applicant]
US 6710036B2
· Kurtzman et al.
· 2004
[cited by applicant]
US 6733757B2
· Patel et al.
· 2004
[cited by applicant]
US 6855314B1
· Chiorini et al.
· 2005
[cited by applicant]
US 6943153B1
· Manning, Jr. et al.
· 2005
[cited by applicant]
US 6962815B2
· Bartlett
· 2005
[cited by applicant]
US 7172893B2
· Rabinowitz et al.
· 2007
[cited by applicant]
US 7252997B1
· Hallek et al.
· 2007
[cited by applicant]
US 7254489B2
· Mossel
· 2007
[cited by applicant]
US 7285381B1
· Hallek et al.
· 2007
[cited by applicant]
US 7314912B1
· Hallek et al.
· 2008
[cited by applicant]
US 7368428B2
· Serrero
· 2008
[cited by applicant]
US 7427396B2
· Arbetman et al.
· 2008
[cited by applicant]
US 7556965B2
· Hallek et al.
· 2009
[cited by applicant]
US 7629322B2
· Kleinschmidt et al.
· 2009
[cited by applicant]
US 7749492B2
· Bartlett et al.
· 2010
[cited by applicant]
US 7892809B2
· Bowles et al.
· 2011
[cited by applicant]
US 7968340B2
· Hallek et al.
· 2011
[cited by applicant]
US 8263396B2
· Xiao
· 2012
[cited by applicant]
US 8524446B2
· Gao et al.
· 2013
[cited by applicant]
US 8574583B2
· Kay et al.
· 2013
[cited by applicant]
US 8632764B2
· Xiao et al.
· 2014
[cited by applicant]
US 8663624B2
· Schaffer et al.
· 2014
[cited by applicant]
US 9193956B2
· Schaffer et al.
· 2015
[cited by applicant]
US 9233131B2
· Schaffer et al.
· 2016
[cited by applicant]
US 9441244B2
· Schaffer et al.
· 2016
[cited by applicant]
US 9457103B2
· Schaffer et al.
· 2016
[cited by applicant]
US 9458517B2
· Schaffer et al.
· 2016
[cited by applicant]
US 9587282B2
· Schaffer et al.
· 2017
[cited by applicant]
US 9856539B2
· Schaffer et al.
· 2018
[cited by applicant]
US 9909142B2
· Yazicioglu et al.
· 2018
[cited by applicant]
US 20020136710A1
· Samulskl et al.
· 2002
[cited by applicant]
US 20030138772A1
· Gao et al.
· 2003
[cited by applicant]
US 20030143732A1
· Fosnaugh et al.
· 2003
[cited by applicant]
US 20030149235A1
· Baker et al.
· 2003
[cited by applicant]
US 20030171254A1
· Sasaki et al.
· 2003
[cited by applicant]
US 20050019927A1
· Hildinger et al.
· 2005
[cited by applicant]
US 20050106558A1
· Perabo et al.
· 2005
[cited by applicant]
US 20050148069A1
· Gage et al.
· 2005
[cited by applicant]
US 20060127358A1
· Muzyczka et al.
· 2006
[cited by applicant]
US 20060188483A1
· Rabinowitz et al.
· 2006
[cited by applicant]
US 20060292117A1
· Loiler et al.
· 2006
[cited by applicant]
US 20070172460A1
· Kleinschmidt et al.
· 2007
[cited by applicant]
US 20100166729A9
· Madison et al.
· 2010
[cited by applicant]
US 20100172871A1
· Flannery et al.
· 2010
[cited by applicant]
US 20110171262A1
· Bakker et al.
· 2011
[cited by applicant]
US 20110236353A1
· Wilson et al.
· 2011
[cited by applicant]
US 20120093772A1
· Horsager et al.
· 2012
[cited by applicant]
US 20130323302A1
· Constable et al.
· 2013
[cited by applicant]
US 20140364338A1
· Schaffer et al.
· 2014
[cited by applicant]
US 20180289757A1
· Schaffer et al.
· 2018
[cited by applicant]
US 20190169237A1
· Schaffer et al.
· 2019
[cited by applicant]
US 20200231942A1
· Schaffer et al.
· 2020
[cited by applicant]
US 20210077552A1
· Schaffer et al.
· 2021
[cited by applicant]
US 20210147876A1
· Ojala et al.
· 2021
[cited by applicant]
US 20220017876A1
· Schaffer et al.
· 2022
[cited by applicant]
US 20220243291A1
· Schaffer et al.
· 2022
[cited by applicant]
US 20220362409A1
· Schaffer et al.
· 2022
[cited by applicant]
US 20230321282A1
· Schaffer et al.
· 2023
[cited by applicant]
AU 2014331708
· 2016
[cited by applicant]
CA 2379220
· 2001
[cited by applicant]
CN 1325451A
· 2001
[cited by applicant]
CN 1826414A
· 2006
[cited by applicant]
CN 1966082A
· 2007
[cited by applicant]
CN 101484005A
· 2009
[cited by applicant]
CN 101532024A
· 2009
[cited by applicant]
CN 103561774A
· 2014
[cited by applicant]
CN 106232618A
· 2014
[cited by applicant]
JP 2008523813A
· 2008
[cited by applicant]
WO WO1997038723
· 1997
[cited by applicant]
WO WO1999067393
· 1999
[cited by applicant]
WO WO2000028004
· 2000
[cited by applicant]
WO WO2001070276
· 2001
[cited by applicant]
WO WO2002053703
· 2002
[cited by applicant]
WO WO2003018820
· 2003
[cited by applicant]
WO WO2003023032
· 2003
[cited by applicant]
WO WO2003054197
· 2003
[cited by applicant]
WO WO2003093436
· 2003
[cited by applicant]
WO WO2004083441
· 2004
[cited by applicant]
WO WO2004083411A1
· 2004
[cited by applicant]
WO WO2004108922
· 2004
[cited by applicant]
WO WO2004112727
· 2004
[cited by applicant]
WO WO2005005610
· 2005
[cited by applicant]
WO WO2005033321
· 2005
[cited by applicant]
WO WO2006066066
· 2006
[cited by applicant]
WO WO2006110689
· 2006
[cited by applicant]
WO WO2007120542
· 2007
[cited by applicant]
WO WO2008131951
· 2008
[cited by applicant]
WO WO2009137006
· 2009
[cited by applicant]
WO WO2009154452
· 2009
[cited by applicant]
WO WO2010093784
· 2010
[cited by applicant]
WO WO2010138263
· 2010
[cited by applicant]
WO WO2011117258
· 2011
[cited by applicant]
WO WO2012145601
· 2012
[cited by applicant]
WO WO2013029030
· 2013
[cited by applicant]
WO WO2013170078
· 2013
[cited by applicant]
WO WO2013173512
· 2013
[cited by applicant]
WO WO2014124282
· 2014
[cited by applicant]
WO WO2014194132
· 2014
[cited by applicant]
WO WO2014207190
· 2014
[cited by applicant]
WO WO2014200910
· 2014
[cited by applicant]
WO WO2015012501A1
· 2015
[cited by applicant]
WO WO2015048534
· 2015
[cited by applicant]
WO WO2015054653
· 2015
[cited by applicant]
WO WO2015121501
· 2015
[cited by applicant]
WO WO2015142941
· 2015
[cited by applicant]
WO WO2015191693
· 2015
[cited by applicant]
WO WO2016034375A1
· 2016
[cited by applicant]
WO WO2016134375
· 2016
[cited by applicant]
WO WO2016141078
· 2016
[cited by applicant]
WO WO2016144892
· 2016
[cited by applicant]
WO WO2017023724
· 2017
[cited by applicant]
WO WO2017197355
· 2017
[cited by applicant]
WO WO2019046069
· 2019
[cited by applicant]
Khabou et al. (2016) “Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant—7m8” Biotechnology and bioengineering, 113(12), 2712-2724. (Year: 2016).
[cited by examiner]
Dalkara et al. (2013) “In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous” Science translational medicine, 5(189), 189ra76, 11 pages. (Year: 2013).
[cited by examiner]
Adachi, et al.; “A New Recombinant Adeno-Associated Virus (AAV)-Based Random Peptide Display Library System: Infection-Defective AAV1.9-3 as a Novel Detargeted Platform for Vector Evolution”; Gene Therapy and Regulation…
[cited by applicant]
Akiyama, et al.; “Intraocular Injection of an Aptamer that Binds PDGF-B: A Potential Treatment for Proliferative Retinopathies”; Journal of Cellular Physiology; vol. 207, pp. 407-412 (2006).
[cited by applicant]
Ali, et al.; “Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy”; Nature Genetics; vol. 25, pp. 306-310 (Jul. 2000).
[cited by applicant]
Allocca, et al.; “Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors”; Journal of Virology; vol. 81, No. 20, pp. 11372-11380 (Oct. 2007).
[cited by applicant]
Asokan, et al., “Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle”; Nat Biotechnol; vol. 28, No. 1, pp. 79-82 (Jan. 2010).
[cited by applicant]
Asuri, et al.; “Directed Evolution of Adena-associated Virus for Enhanced Gene Delivery and Gene Targeting in Human Pluripotent Stem Cells”; Molecular Therapy, vol. 20, No. 2, pp. 329-338 (Feb. 1, 2012).
[cited by applicant]
Bichsel, et al.; “Bacterial delivery of nuclear proteins into pluripotent and differentiated cells”; PLoS One; vol. 6, No. 1, pp. 1-9 (Jan. 2011).
[cited by applicant]
Blacklow, et al.; “A Seroepidemiologic Study of Adenovirus-Associated Virus Infection in Infants and Children”; Am J Epidemiol.; vol. 94, No. 4, pp. 359-366 (Oct. 1971).
[cited by applicant]
Boucas, et al.; “Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations”; J Gene Med.; vol. 11, No. 12, pp. 1103-1113 (Dec. 2009).
[cited by applicant]
Buch, et al., “in Contrast to AAC-Mediated Cntf Expression, AAV-Mediated Gdnf Expression Enhances Gene Replacement Therapy in Rodent Models of Retinal Degeneration”; Molecular Therapy; vol. 14, No. 5, pp. 700-709 (Nov. …
[cited by applicant]
Buning, et al., “Receptor targeting of adeno-associated virus vectors”; Gene Therapy; vol. 10, pp. 1142-1151 (2003).
[cited by applicant]
Chadderton, et al.; “Improved Retinal Function in a Mouse Model of Dominant Retinitis Pigmentosa Following AAV-delivered Gene Therapy”; Molecular Therapy; vol. 17, No. 4, pp. 593-599 (Apr. 2009).
[cited by applicant]
Choi, et al.; “AAV Hybrid Serotypes: Improved Vectors for Gene Delivery.”; Current Gene Therapy; vol. 5, No. 3, pp. 299-310 (Jun. 2005).
[cited by applicant]
Cronin, et al.; “Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter”; EMBO Molecular Medicine; 16 pages (2014).
[cited by applicant]
Dalkara, et al.; “In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous”; Science Translational Medicine; vol. 5, Issue 187, 11 pages (Jun. 12, 2013).
[cited by applicant]
Dalkara, et al.; “Developing Photoreceptor Targeted AAV Variant by Directed Evolution”; ARVO Annual Meeting Abstract Search and Program Planner; vol. 2011, pp. 4381 (May 2011).
[cited by applicant]
Database Geneseq [Online] Oct. 16, 2008 (Oct. 16, 2008), “Modified Adena-associated virus (hu.44) capsid protein, VP1, hu.44R2.”, retrieved from EBI accession No. GSP:AEL63853, Database accession No. AEL63853.
[cited by applicant]
Database Geneseq [Online] Oct. 16, 2008 (Oct. 16, 2008), “Modified Adena-associated virus (hu.44) capsid protein, VP1, hu.44R3.”, retrieved from EBI accession No. GSP:AEL63854, Database accession No. AEL63854.
[cited by applicant]
Davidson, et al.; “Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.”; Proc Natl Acad Sci USA.; vol. 97, No. 7, pp. 3428…
[cited by applicant]
Day, et al.; “Advances in AAV Vector Development for Gene Therapy in the Retina”; Adv. Exp. Med. Biol.; vol. 801, pp. 687-693 (2014).
[cited by applicant]
Den Dunnen, et al.; “Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.”; Human Mutation; vol. 15, pp. 7-12 (2000).
[cited by applicant]
Diprimio, et al.; “Surface loop dynamics in adeno-associated virus capsid assembly”; Journal of Virology; vol. 82, No. 11, pp. 5178-5189 (Jun. 2008).
[cited by applicant]
Erles, et al.; “Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).”; J Med Virol.; vol. 59, No. 3, pp. 406-411 (Nov. 1999).
[cited by applicant]
Excoffon, et al.; “Directed evolution of adeno-associated virus to an infectious respiratory virus”; Proc Natl Acad Sci USA; vol. 106, No. 10, pp. 3865-3870 (Mar. 10, 2009).
[cited by applicant]
Flotte, et al.; “Gene expression from adeno-associated virus vectors in airway epithelial cells”; Am J Respir Cell Mol Biol.; vol. 7, No. 3, pp. 349-356 (Sep. 1992).
[cited by applicant]
Gen Bank accession No. AAZ79678; rat AAV1 VP3 capsid protein sequence downloaded from NCBI; downloaded on Nov. 3, 2008.
[cited by applicant]
GenBank accession No. ABZ10812; AAV13 capsid protein sequence downloaded from NCBI; downloaded on Nov. 3, 2008.
[cited by applicant]
Girod, et al.; “Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2”; Nat. Med.; vol. 5, No. 9, pp. 1052-1056 (Sep. 1999).
[cited by applicant]
Gray, et al.; “Directed Evolution of a Novel Adeno-associated Virus (AAV) Vector That Crosses the Seizure-compromised Blood-Brain Barrier (BBB)”; Molecular Therapy; vol. 18, No. 3, pp. 570-578 (2010).
[cited by applicant]
Gregory-Evans, et al.; “Ex vivo Gene Therapy Using Intravitreal Injection of GDNF-secreting Mouse Embryonic Stem Cells in a Rat Model of Retinal Degeneration”; Molecular Vision; vol. 15, pp. 962-973 (May 13, 2009).
[cited by applicant]
Grieger, et al.; “Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly”; Journal of Virology; vol. 80, No. 11, pp. 5199-5210 (2006).
[cited by applicant]
Grifman, et al.; “Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids”; Molecular Therapy; vol. 3, No. 6, pp. 964-975 (Jun. 2001).
[cited by applicant]
Grimm, et al.; “In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses”; Journal of Virology; vol. 82, No. 12, pp. 5887-5911 (Jun. 2008).
[cited by applicant]
Halbert, et al.; “Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes.” J. Virol.; vol. 74, No. 3, pp. 1524-1532 (Feb. 2000).
[cited by applicant]
Hellstrom, et al.; “Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection”; Gene Therapy; vol. 16, pp. 521-532 (2009).
[cited by applicant]
Hirsch, et al.; “Directed Evolution of the AAV Capsid for Human Embryonic Stem Cell Transduction”; Molecular Therapy; vol. 17, Supp. 1, S177-S178 (May 2009).
[cited by applicant]
Huttner, et al “Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce Affinity to Human Serum Antibodies and Overcome Potential Limitations of Neutralizing Antibodies for the Used in Human Gene Therap…
[cited by applicant]
Huttner, et al.; “Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.”; Gene Ther; vol. 10, pp. 2139-2147 (Dec. 2003).
[cited by applicant]
Jang, et al.; “An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells”; Mol Ther.; vol. 19, No. 4, pp. 667-675 (Apr. 2011).
[cited by applicant]
Jeune, et al.; “Pre-existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy”; Human Gene Therapy Methods; vol. 24, pp. 59-67 (Apr. 2013).
[cited by applicant]
Karp, et al.; “An in vitro model of differentiated human airway epithelia, Methods for establishing primary cultures”; Methods Mol Biol.; vol. 188, pp. 115-137 (2002).
[cited by applicant]
Kern, et al.; “Identification of a heparin-binding motif on adeno-associated virus type 2 capsids”; Journal of Virology; vol. 77, No. 20, pp. 11072-11081 (Oct. 2003).
[cited by applicant]
Khabou, et al.; “Insight Into the Mechanisms of Enhanced Retinal Transduction by the Engineered AAV2 Capsid Variant—7m8”; Biotechnology and Bioengineering; vol. 113, No. 12, pp. 2712-2724 (Dec. 2016).
[cited by applicant]
Khani, et al.; “AAV-Mediated Expression Targeting of Rod and Cone Photoreceptors with a Human Rhodopsin Kinase Promoter”; Investigative Ophthalmology & Visual Science; vol. 48, No. 9, pp. 3954-3961 (Sep. 2007).
[cited by applicant]
Klimczak, et al.; “A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Muller Cells”; PLoS ONE; vol. 4, No. 10, pp. 1-10 (Oct. 2009).
[cited by applicant]
Klimczak; “Molecular Evolution of Adeno-associated Virus for Improved Retinal Gene Therapies”; Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Molecular and Ce…
[cited by applicant]
Koerber, et al.; “DNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny”; Molecular Therapy; vol. 16, No. 10, pp. 1703-1709 (Oct. 2008).
[cited by applicant]
Koerber, et al.; “Engineering of a Novel AAV Vector In a Human Airway Model System for Cystic Fibrosis Gene Therapy”; AlChE Annual Meeting Abstract, 3 pages (Nov. 29, 2008).
[cited by applicant]
Koerber, et al.; “Molecular Evolution of Adeno-associated Virus for Enhanced Glial Gene Delivery”, Molecular Therapy; vol. 17, No. 12, pp. 2088-2095 (Dec. 2009).
[cited by applicant]
Kotin et al., (2017) “Geneseq Accession No. BDN88104”, computer printout, 2 pages.
[cited by applicant]
Kotterman, et al.; “Engineering adeno-associated viruses for clinical gene therapy”; Nat Rev Genet; vol. 15, No. 7, pp. 445-451 (Jul. 1, 2014).
[cited by applicant]
Kotterman, et al.; “Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant”; Development; vol. 142, pp. 1885-1892 (2015).
[cited by applicant]
Kwon, et al.; “Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer”; Pharmaceutical Research; vol. 25, No. 3, pp. 489-499 (Mar. 2008).
[cited by applicant]
Lai, et al.; “Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys”; Mol Ther.; vol. 12, No. 4, pp. 659-668 (Oct. 2005).
[cited by applicant]
Lee, at al.; “Adena-associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering”; Current Opinion in Biomedical Engineering; pp. 7:58-7:63 (2018).
[cited by applicant]
Li, et al.; “Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles”; Molecular Therapy; vol. 16, No. 7, pp. 1252-1260 (Jul. 2008).
[cited by applicant]
Li, et al.; “Generation of Novel AAV Variants by Directed Evolution for Improved CFTR Delivery to Human Ciliated Airway Epithelium”; Molecular Therapy; vol. 17, No. 12, pp. 2067-2077 (Dec. 2009).
[cited by applicant]
Limberis, et al.; “Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered”; Proc Natl Acad Sci USA; vol. 103, No. 35, pp. 12993-12998 (Aug. 29, 2006).
[cited by applicant]
Loiler, et al.; “Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver”; Gene Ther.; vol. 10, pp. 1551-1558 (2003).
[cited by applicant]
Maguire, et al.; “Directed evolution of adeno-associated virus for glioma cell transduction”; J. Neurooncol.; vol. 96, pp. 337-347 (2010).
[cited by applicant]
Maheshri, et al.; “Directed evolution of adeno-associated virus yields enhanced gene delivery vectors”; Nature Biotechnology; vol. 24, No. 2, pp. 198-204 (Feb. 2006).
[cited by applicant]
McCullum, et al.; “Random Mutagenesis by Error-Prone PCR”; Methods Mol Biol.; vol. 634, pp. 103-109; doi: 10.1007/978-1-60761-652-8_7 (2010).
[cited by applicant]
McGee, et al., “Glial Cell Line Derived Neurotrophic Factor Delays Photoreceptor in a Transgenic Rat Model of Retinitis Pigmentosa”; Molecular Therapy; vol. 4, No. 6, pp. 622-629 (Dec. 2001).
[cited by applicant]
Michelfelder, et al.; “Successful Expansion but Not Complete Restriction of Tropism of Adeno-Associated Virus by In Vivo Biopanning of Random Virus Display Peptide Libraries”; PLoS One; vol. 4, No. 4, pp. 1-13 (Apr. 200…
[cited by applicant]
Michelfelder, et al.; “Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy”; Experimental Hematology; vol. 35, pp. 1766-1776 (2007).
[cited by applicant]
Mitchell, et al.; “AAV's anatomy: Roadmap for optimizing vectors for translational success”; Curr Gene Ther.; vol. 10, No. 5, pp. 319-340 (Oct. 2010).
[cited by applicant]
Miyake, et al.; “Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors”; Brain Research; vol. 1389, pp. 19-26 (2011).
[cited by applicant]
Moskalenko, et al; “Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.”; J. Virol.; vol. 74, No. 4, pp. 1761-1766 (Feb. 2000).
[cited by applicant]
Muller, et al.; “Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors”; Nat Biotechnol; vol. 21, No. 9, pp. 1040-1046 (Sep. 2003).
[cited by applicant]
Nguyen, et al; “Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain.”; Neuroreport; vol. 12, No. 9, pp. 1961-1964 (Jul. 3, 2001).
[cited by applicant]
Nicklin, et al.; “Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells”; Mol. Ther.; vol. 4, No. 2, pp. 174-181 (Aug. 2001).
[cited by applicant]
Opie, et al.; “Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 that Contribute to Heparan Sulfate Proteoglycan Binding”; Journal of Virology; vol. 77, No. 12, pp. 6995-7006 …
[cited by applicant]
Ortolano, et al.; “Present and Future of Adeno Associated Virus Based Gene Therapy Approaches”; Recent Patents on Endocrine, Metabolic & Immune Drug Discovery; vol. 6, pp. 47-66 (2012).
[cited by applicant]
Paddison, et al.; “Stable suppression of gene expression by RNAi in mammalian cells”; Proc. Nat'l Acad. Sci. USA; vol. 99, No. 3, pp. 1443-1448 (Feb. 5, 2002).
[cited by applicant]
Padron, et al.; “Structure of adeno-associated virus type 4”; Journal of Virology; vol. 79, No. 8, pp. 5047-5058 (Apr. 2005).
[cited by applicant]
Park, et al.; “Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse”; Gene Therapy; vol. 16, pp. 916-926 (2009).
[cited by applicant]
Pechan, et al; “Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.”; Gene. Ther.; vol. 16, No. 1, pp. 10-16 (Jan. 2009).
[cited by applicant]
Perabo, et al.; “Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus”; The Journal of Gene Medicine; vol. 8, No. 2, pp. 155-162 (Feb. 2006).
[cited by applicant]
Perabo, et al.; “Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism”; Journal of Virology; vol. 80, No. 14, pp. 7265-7269 (Jul. 2006).
[cited by applicant]
Perabo, et al.; “In Vitro Selection of Viral Vectors with Modified Tropism: The Adeno-associated Virus Display”; Molecular Therapy; vol. 8, No. 1, pp. 151-157 (Jul. 2003).
[cited by applicant]
Petrs-Silva, et al.; “High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors”; Molecular Therapy; vol. 17, No. 3, pp. 463-471 (Mar. 2009).
[cited by applicant]
Popa-Wagner, et al.; “Impact of VP1-Specific Protein Sequence Motifs on Adeno-Associated Virus Type 2 Intracellular Trafficking and Nuclear Entry”; Journal of Virology; vol. 86, No. 17, pp. 9163-9174 (Sep. 2012).
[cited by applicant]
Rabinowitz, et al.; “Building a Better Vector: The Manipulation of AAV Virions”; Virology; vol. 278, pp. 301-308 (2000).
[cited by applicant]
Rabinowitz, et al.; “Insertional mutagenesis of AAV2 capsid and the production of recombinant virus.”; Virology; vol. 265, No. 2, pp. 274-285 (Dec. 20, 1999).
[cited by applicant]
Rayaprolu, et al.; “Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics”; Journal of Virology; vol. 87, No. 24, pp. 13150-13160 (Dec. 2013).
[cited by applicant]
Ried, et al.; “Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors”; J. Virol.; vol. 76, No. 9, pp. 4559-4566 (May 2002…
[cited by applicant]
Ryals, et al.; “Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines”; Mol Vision; vol. 17, pp. 1090-1102 (Apr. 2011).
[cited by applicant]
Santiago-Ortiz, et al.; “AAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants”; Gene. Ther.; vol. 22, No. 12, pp. 934-946 (Dec. 2015).
[cited by applicant]
Schaffer et al., 2014, Geneseq Accession No. BBR00471, computer printout, pp. 1-2.
[cited by applicant]
Schaffer, et al.; “Directed evolution of AAV vector mutants for enhanced gene delivery”; Abstracts of Papers American Chemical Society; vol. 227, Part 1, p. U214 (Mar. 2004).
[cited by applicant]
Shao, et al.; “Gene Transfer to the Gastrointestinal Tract After Peroral Administration of Recombinant Adeno-associated Virus Type 2 Vectors”; Journal of Pediatric Gastroenterology and Nutrition; vol. 43, pp. 168-179 (A…
[cited by applicant]
Shen, et al.; “Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency”; Mol Ther.; vol. 15, No. 11, pp. 1955-1962 (Aug. 28, 2007).
[cited by applicant]
Shen, et al.; “Multiple Roles for Sialylated Glycansin Determining the Cardiopulmonary Tropism of Adeno-Associated Virus 4”; Journal of Virology; vol. 87, No. 24, pp. 13206-13213 (Dec. 2013).
[cited by applicant]
Shi, et al.; “Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma”; Gynecol. Oncol.; vol…
[cited by applicant]
Shi, et al.; “Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin-binding ability and introduced novel tropism”; Hu…
[cited by applicant]
Shi, et al.; “RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism”; Mol. Ther.; vol. 7, No. 4, pp. 515-525 (Apr. 2003).
[cited by applicant]
Shi, W. et al.; “Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors”; Human Gene Therapy; vol. 12, pp. 1697-1711…
[cited by applicant]
Sonntag, et al.; “Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus”; Journ…
[cited by applicant]
Steinbach, et al.; “Assembly of adeno-associated virus type 2 capsids in vitro” J of Gen Virology; vol. 78, pp. 1453-1462 (1997).
[cited by applicant]
Sullivan, et al.; “Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain”; Gene Therapy; vol. 25, pp. 205-219 (2018).
[cited by applicant]
Sun, et al.; “Immune responses to adeno-associated virus and its recombinant vectors”; Gene Therapy; vol. 10, pp. 964-976 (2003).
[cited by applicant]
Surace, et al.; “Delivery of Adeno-Associated Virus Vectors to the Fetal Retina: Impact of Viral Capsid Proteins on Retinal Neuronal Progenitor Transduction”; Journal of Virology; vol. 77, No. 14, pp. 7957-7962 (Jul. 20…
[cited by applicant]
Takada, et al.; “Synaptic Pathology in Retinoschisis Knockout (Rs1
[cited by applicant]
Tal; “Adeno-Associated Virus-Based Vectors in Gene Therapy”; Journal of Biomedical Science; vol. 7, No. 4, pp. 279-291 (Jul. 2000).
[cited by applicant]
Tervo, et al.; “A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons”; Neuron; vol. 92, pp. 372-382 (2016).
[cited by applicant]
Tomar, et al.; “Use of Adeno-Associated Viral Vector for Delivery of Small Interfering RNA”; Oncogene; vol. 22, No. 36, pp. 5712-5715 (Aug. 28, 2003).
[cited by applicant]
UniProtKB database: B4Y881_9VIRU; “Capsid protein VP1, adeno-associated virus”; 6 pages (Sep. 23, 2008).
[cited by applicant]
Van Vliet, et al.; “Proteolytic mapping of the adeno-associated virus capsid”; Mol Ther.; vol. 14, No. 6, pp. 809-821 (Dec. 2006).
[cited by applicant]
Venkatakrishnan, et al.; “Structure and Dynamics of Adeno-Associated Virus Serotype 1 VP1-Unique N-Terminal Domain and Its Role in Capsid Trafficking”; Journal of Virology; vol. 87, No. 9, pp. 4974-4984 (May 2013).
[cited by applicant]
Watanabe, et al.; “Tropisms of AAV for Subretinal Delivery to the Neonatal Mouse Retina and Its Application for In Vivo Rescue of Developmental Photoreceptor Disorders”; PLoS ONE; vol. 8, No. 1, 12 pages (Jan. 15, 2013).
[cited by applicant]
Waterkamp, et al.; “Isolation of targeted AAV2 vectors from novel virus display libraries”; J. Gene. Med.; vol. 8, pp. 1307-1319 (Sep. 6, 2006).
[cited by applicant]
White, et al.; “Genetic Modification of Adeno-Associated Viral Vector Type 2 Capsid Enhances Gene Transfer Efficiency in Polarized Human Airway Epithelial Cells”; Human Gene Therapy; vol. 19, pp. 1407-1414 (Dec. 2008).
[cited by applicant]
White, et al.; “Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors”; Circulation; vol. 109, pp. 513-519 (Feb. 3, 2004).
[cited by applicant]
Wickham, et al.; “Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins”; Journal of Virology; vol. 71, No. 11, pp. 8221-8229 (Nov. 1997).
[cited by applicant]
Willett, et al.; “Immunology of AAV-mediated gene transfer in the eye”; Frontiers in Immunology; vol. 4, No. 261, 8 pages (Aug. 2013).
[cited by applicant]
Wobus, et al.; “Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infecti…
[cited by applicant]
Work, et al.; “Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses”; Mol. Ther.; vol. 13, No. 4, pp. 683-693 (Apr. 2006).
[cited by applicant]
Wu, et al.; “Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism”; Journal of Virology; vol. 74, No. 18, pp. 8635-8647 (Sep. 2000).
[cited by applicant]
Wu, et al.; “α2,3 and α2,6 N-linked Sialic Acids Facilitate Efficient Binding and Transduction by Adeno-Associated Virus Types 1 and 6”; Journal of Virology; vol. 80, No. 18, pp. 9093-9103 (Sep. 2006).
[cited by applicant]
Xiao, et al.; “Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2”; Journal of Virology; vol. 76, No. 22, pp. 11505-11517 (Nov. 2002).
[cited by applicant]
Xie, et al.; “The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy”; PNAS; vol. 99, No. 16, pp. 10405-10410 (Aug. 6, 2002).
[cited by applicant]
Yang, et al.; “A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection”; PNAS; vol. 106, No. 10, pp. 3946-3951 (Mar. 10, 2009).
[cited by applicant]
Yang, et al.; “Directed Evolution of Adeno-Associated Virus (AAV) as Vector for Muscle Gene Therapy”; Methods in Molecular Biology; vol. 709, pp. 127-139 (2011).
[cited by applicant]
Yu; “Current Approaches and Future Directions of Gene Therapy in Alzheimer's Disease”; Neurochemical Journal; vol. 5, No. 3, pp. 159-168 (2011).
[cited by applicant]
Zabner, et al.; “Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer”; J Virol.; No. 74, No. 8, pp. 3852-3858 (Apr. 2000).
[cited by applicant]
Zhao, et al.; “Molecular evolution by staggered extension process (StEP) in vitro recombination”; Nat Biotechnol; vol. 16, No. 3, pp. 258-261 (Mar. 1998).
[cited by applicant]
Zincarelli, et al.; “Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection”; Molecular Therapy; vol. 16, No. 6, pp. 1073-1080 (Jun. 2008).
[cited by applicant]
Zolotukhin, et al.; “Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield”; Gene Therapy; vol. 6, pp. 973-985 (1999).
[cited by applicant]
Weinstein, et al., “New Methods in Engineering Adeno-Associated Virus (AAV) for Improved Gene Delivery.” Dissertaion from University of California, Berkeley, Dissertation No. 3720891, ProQuest ID: 1726005971, https://di…
[cited by applicant]
Bantel-Schaal et al., (1999) “Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses.”, J. Virol., 73:939-947.
[cited by applicant]
Third-Party Submission dated Mar. 15, 2022, U.S. Appl. No. 16/315,032, 95 pages.
[cited by applicant]
Antonarakis, “Recommendations for a nomenclature system for human gene mutations”, Human Mutation, 1998, 11(1):1-3.
[cited by applicant]
Arbetman et al., “Caprine adeno-associated virus capsid protein VPI”, Score result 33 for WO2004112727A2, Accession No. ADV70291, Dec. 29, 2004, 3 pages.
[cited by applicant]
Bantel-Schaal et al., “Score result: Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses, Gene Accession No. Y18065”, 1999, 4 pages.
[cited by applicant]
Bantel-Schaal et al., “Score result: Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses, Gene Accession No. Q9YIJ1, integrated into UniProtKB/TrEMBL on May…
[cited by applicant]
Dimattia et al., “Structural insight into the unique properties of adeno-associated virus serotype 9”, Journal of Virology, Jun. 2012, 86(12):6947-6958.
[cited by applicant]
Douar, et al., “Deleterious effect of peptide insertions in a permissive site of the AAV2 capsiD”, Virology, May 10, 2003, 309(2):203-208.
[cited by applicant]
Gurda et al., “Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8”, Journal of Virology, Aug. 2012, 86(15): 7739-7751.
[cited by applicant]
Klimczak et al., “Molecular engineering of adeno-associated virus yields a novel variant with efficient intravitreal transduction of Muller cells”, Molecular Therapy, May 2009, 17:Supplement 1:S178.
[cited by applicant]
Koerber et al., “Molecular evolution of adeno-associated virus for enhanced glial gene delivery”, Molecular Therapy, Dec. 2009, 17(12):2088-2095.
[cited by applicant]
Koerber, “Engineering Adeno-associated Viral Vectors with Novel Structure-Function Relationships for Improved Gene Delivery”, Koerber Dissertation, University of California, Berkeley, 2008, 323 pages.
[cited by applicant]
Lane et al., “Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8”, Acta Crystallographica Section F Structural Biology and Crystallization Communications, Jun. …
[cited by applicant]
Lerch et al., “The structure of adeno-associated virus serotype 3B (AAV-3B): Insights into receptor binding and immune evasion”, Virology, Jul. 20, 2010, 403(1):26-36.
[cited by applicant]
Lochrie et al., “Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization”, Journal of Virology, Jan. 2006, 80(2):821-834.
[cited by applicant]
Mace et al., “Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores on and off visual responses in blind mice”, Molecular Therapy, Jan. 2015, 23(1):7-16.
[cited by applicant]
McCraw, “Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20”, Virology, Sep. 2012, 431(1-2):40-49.
[cited by applicant]
Miller et al., “Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1”, Acta Crystallographica Section F Structural Biology and Crystallization Communications, Dec.…
[cited by applicant]
Nam et al., “Structure of adeno-associated virus serotype 8, a gene therapy vector”, Journal of Virology, Nov. 2007, 81(22):12260-12271.
[cited by applicant]
Petrs-Silva et al., “Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina”, Molecular Therapy, Feb. 2011, 19(2):293-301.
[cited by applicant]
Samulski et al., “Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV”, Cell, May 1983, 33(1):135-143.
[cited by applicant]
Tse et al., “Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion”, Proceedings of the National Academy of Sciences of the United States of America, Jun. 13, 2017, 114(…
[cited by applicant]
Walters et al., “Structure of Adeno-Associated Virus Serotype 5”, Journal of Virology, Apr. 2004, 78(7):3361-3371.
[cited by applicant]
Wu et al., “Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes”, Journal of Virology, Nov. 2006, 80(22):11393-11397.
[cited by applicant]
Xie et al., “Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6)”, Virology, Nov. 10, 2011, 420(1):10-19.
[cited by applicant]
Xue et al., “CRALBP supports the mammalian retinal visual cycle and cone vision”, The Journal of Clinical Investigation, Feb. 2015, 125(2):727-738.
[cited by applicant]